Inspira Technologies Terminates Sales Agreement with A.G.P.
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 5 hours ago
0mins
Should l Buy IINN?
Inspira Technologies announced the termination of its sales agreement with A.G.P./Alliance Global Partners, dated February 17 and its standby equity purchase agreement with YA II PN, dated December 12, 2025. The company has delivered formal written notices to terminate these financing facilities, with no outstanding obligations or further advances to be made under either agreement by either of the parties to the respective agreements.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy IINN?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on IINN
About IINN
Inspira Technologies Oxy B.H.N Ltd, formerly Insense Medical Ltd, incorporated on February 27, 2018, is a specialty medical device company based in Israel. The Company is engaged in the research, development, manufacture, and marketing of respiratory support technology that is intended to provide an alternative to invasive mechanical ventilation (MV). It provides patients with acute respiratory distress syndrome to maintain spontaneous breathing and avoid the various risks associated with the use of MV.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Inspira Technologies Terminates Financing Agreements to Optimize Capital Structure
- Termination of Financing Agreements: Inspira Technologies announced the termination of its sales agreement with A.G.P./Alliance Global Partners and standby equity purchase agreement with YA II PN Ltd, demonstrating the company's commitment to disciplined capital management.
- No Outstanding Obligations: The company stated that it has issued formal notices to end both financing arrangements, with neither party having any outstanding obligations or further advances, ensuring financial clarity and stability.
- Strategic Focus Shift: This termination reflects Inspira's preparation for its next strategic phase, emphasizing a cautious approach to capital operations as it aligns its resources for future growth.
- Market Reaction: Following this announcement, Inspira Technologies' stock price fell 2.03% in premarket trading to $0.389, indicating market concern regarding the company's adjustments to its financing strategy.
See More
Inspira Technologies Reports Disappointing FY Revenue and Increased Losses
- Disappointing Financial Performance: Inspira Technologies reported FY 2025 revenue of $0.3 million, missing expectations by $0.19 million, indicating significant pressure in market competition that may affect future financing capabilities.
- Increased R&D Expenses: For the twelve months ending December 31, 2025, R&D expenses rose to $7.496 million from $6.323 million in 2024, reflecting an 18.5% increase; however, this spending has not effectively translated into revenue, highlighting slow progress in technology development.
- Widening Net Loss: The net loss for FY 2025 was $13.22 million, a 19.6% increase from the $11.053 million loss in 2024, raising concerns among investors about the company's financial health and potentially impacting stock performance.
- Tightening Cash Flow: As of December 31, 2025, cash and cash equivalents totaled $3.159 million, down 45.4% from $5.779 million in 2024, indicating reduced liquidity that may constrain the company's operational and growth capabilities.
See More
Inspira Technologies Reports 2025 Financial Results and Strategic Updates
- Clinical Validation Progress: In April 2025, Inspira successfully treated its first patient using the ART100 system at Westchester Medical Center, marking a critical milestone in validating the system's real-world clinical performance, with subsequent deployments at multiple leading medical centers in the U.S. expanding its clinical application.
- Initial Commercial Success: In mid-2025, Inspira secured binding purchase orders totaling $49.5 million, representing its first large-scale commercial commitments, with revenue expected to be primarily recognized in 2026, demonstrating the company's initial success in the medical device market.
- Increased R&D Spending: Research and development expenses reached $7.496 million in 2025, up from $6.323 million in 2024, primarily due to higher share-based compensation and exchange rate fluctuations, reflecting the company's ongoing investment in technology development.
- Enhanced Liquidity: The company completed a registered direct offering at year-end, raising approximately $4.75 million, strengthening its liquidity to support commercial execution and strategic initiatives in 2026, ensuring compliance with Nasdaq's shareholder equity requirements for continued listing.
See More
Inspira Technologies Deploys ART100 System at Leading U.S. Hospital
- Market Expansion: Inspira Technologies has deployed its FDA-cleared INSPIRA™ ART100 system at a leading U.S. academic medical center, further expanding its presence in the Tier-1 hospital market, which is expected to enhance the company's market share in the medical device sector.
- Clinical Evaluation Initiation: The ART100 system has been integrated into the center's clinical workflow to support a structured evaluation aimed at defining clinical protocols and facilitating broader institutional adoption, paving the way for future commercialization.
- Strategic Execution: Mike Hershkovitz, Global VP Sales, stated that this deployment represents a continued execution of the company's U.S. commercial strategy, demonstrating that the ART100 meets the operational and clinical demands of top-tier healthcare providers, thereby strengthening the company's competitive position in the industry.
- Future Development Potential: Inspira Technologies is advancing the development of the next-generation INSPIRA ART500 system, designed to provide oxygenation support while patients remain awake, further solidifying its market position within the life-support and MedTech landscape.
See More
Inspira Technologies Showcases FDA-Cleared ART100 System
- Strategic Showcase: Inspira Technologies will present its FDA-cleared INSPIRA™ ART100 system at the AmSECT International Conference from March 25-29, 2026, in Austin, Texas, aiming to engage clinical decision-makers who influence hospital purchasing decisions and enhance market visibility.
- Leveraging FDA Approval: The ART100 system, which received FDA 510(k) clearance in May 2024, will be showcased to validate its readiness for clinical integration in cardiopulmonary bypass procedures, thereby accelerating market penetration.
- Active Distribution Channel: The collaboration with Glo-Med Networks Inc. for the presentation demonstrates Inspira's active commercial pipeline, marking a transition from development to sales execution and market visibility, enhancing its competitive position.
- Key Phase in Commercial Strategy: Global VP Sales Mike Hershkovitz noted that this event represents a critical phase in the company's U.S. commercial strategy, aimed at expanding clinical partnerships and distribution footprint to drive rapid market share growth.
See More
Inspira Technologies Secures Major Procurement Approval
- Stock Surge: Inspira Technologies OXY (IINN) shares surged over 28% in pre-market trading on Monday, reflecting strong market interest and heightened investor confidence in the company's new product.
- Procurement Approval: Israel's largest health services provider, Clalit Health Services, approved the procurement of Inspira's FDA-cleared ART100 platform, marking a significant milestone in the medical device sector for the company.
- Market Reach: The ART100 system will be rapidly deployed across Clalit’s healthcare network, which serves approximately 4.9 million members, indicating a swift expansion of the company's market share and enhanced brand presence.
- Clinical Validation: The approval of ART100 represents not only a successful regulatory clearance but also strong clinical validation for its application in cardiopulmonary bypass and ECMO procedures, signaling substantial future commercial growth potential.
See More
Inspira Technologies Terminates Financing Agreements to Optimize Capital Structure
- Termination of Financing Agreements: Inspira Technologies announced the termination of its sales agreement with A.G.P./Alliance Global Partners and standby equity purchase agreement with YA II PN Ltd, demonstrating the company's commitment to disciplined capital management.
- No Outstanding Obligations: The company stated that it has issued formal notices to end both financing arrangements, with neither party having any outstanding obligations or further advances, ensuring financial clarity and stability.
- Strategic Focus Shift: This termination reflects Inspira's preparation for its next strategic phase, emphasizing a cautious approach to capital operations as it aligns its resources for future growth.
- Market Reaction: Following this announcement, Inspira Technologies' stock price fell 2.03% in premarket trading to $0.389, indicating market concern regarding the company's adjustments to its financing strategy.
See More
Inspira Technologies Reports Disappointing FY Revenue and Increased Losses
- Disappointing Financial Performance: Inspira Technologies reported FY 2025 revenue of $0.3 million, missing expectations by $0.19 million, indicating significant pressure in market competition that may affect future financing capabilities.
- Increased R&D Expenses: For the twelve months ending December 31, 2025, R&D expenses rose to $7.496 million from $6.323 million in 2024, reflecting an 18.5% increase; however, this spending has not effectively translated into revenue, highlighting slow progress in technology development.
- Widening Net Loss: The net loss for FY 2025 was $13.22 million, a 19.6% increase from the $11.053 million loss in 2024, raising concerns among investors about the company's financial health and potentially impacting stock performance.
- Tightening Cash Flow: As of December 31, 2025, cash and cash equivalents totaled $3.159 million, down 45.4% from $5.779 million in 2024, indicating reduced liquidity that may constrain the company's operational and growth capabilities.
See More
Inspira Technologies Reports 2025 Financial Results and Strategic Updates
- Clinical Validation Progress: In April 2025, Inspira successfully treated its first patient using the ART100 system at Westchester Medical Center, marking a critical milestone in validating the system's real-world clinical performance, with subsequent deployments at multiple leading medical centers in the U.S. expanding its clinical application.
- Initial Commercial Success: In mid-2025, Inspira secured binding purchase orders totaling $49.5 million, representing its first large-scale commercial commitments, with revenue expected to be primarily recognized in 2026, demonstrating the company's initial success in the medical device market.
- Increased R&D Spending: Research and development expenses reached $7.496 million in 2025, up from $6.323 million in 2024, primarily due to higher share-based compensation and exchange rate fluctuations, reflecting the company's ongoing investment in technology development.
- Enhanced Liquidity: The company completed a registered direct offering at year-end, raising approximately $4.75 million, strengthening its liquidity to support commercial execution and strategic initiatives in 2026, ensuring compliance with Nasdaq's shareholder equity requirements for continued listing.
See More
Inspira Technologies Deploys ART100 System at Leading U.S. Hospital
- Market Expansion: Inspira Technologies has deployed its FDA-cleared INSPIRA™ ART100 system at a leading U.S. academic medical center, further expanding its presence in the Tier-1 hospital market, which is expected to enhance the company's market share in the medical device sector.
- Clinical Evaluation Initiation: The ART100 system has been integrated into the center's clinical workflow to support a structured evaluation aimed at defining clinical protocols and facilitating broader institutional adoption, paving the way for future commercialization.
- Strategic Execution: Mike Hershkovitz, Global VP Sales, stated that this deployment represents a continued execution of the company's U.S. commercial strategy, demonstrating that the ART100 meets the operational and clinical demands of top-tier healthcare providers, thereby strengthening the company's competitive position in the industry.
- Future Development Potential: Inspira Technologies is advancing the development of the next-generation INSPIRA ART500 system, designed to provide oxygenation support while patients remain awake, further solidifying its market position within the life-support and MedTech landscape.
See More
Inspira Technologies Showcases FDA-Cleared ART100 System
- Strategic Showcase: Inspira Technologies will present its FDA-cleared INSPIRA™ ART100 system at the AmSECT International Conference from March 25-29, 2026, in Austin, Texas, aiming to engage clinical decision-makers who influence hospital purchasing decisions and enhance market visibility.
- Leveraging FDA Approval: The ART100 system, which received FDA 510(k) clearance in May 2024, will be showcased to validate its readiness for clinical integration in cardiopulmonary bypass procedures, thereby accelerating market penetration.
- Active Distribution Channel: The collaboration with Glo-Med Networks Inc. for the presentation demonstrates Inspira's active commercial pipeline, marking a transition from development to sales execution and market visibility, enhancing its competitive position.
- Key Phase in Commercial Strategy: Global VP Sales Mike Hershkovitz noted that this event represents a critical phase in the company's U.S. commercial strategy, aimed at expanding clinical partnerships and distribution footprint to drive rapid market share growth.
See More
Inspira Technologies Secures Major Procurement Approval
- Stock Surge: Inspira Technologies OXY (IINN) shares surged over 28% in pre-market trading on Monday, reflecting strong market interest and heightened investor confidence in the company's new product.
- Procurement Approval: Israel's largest health services provider, Clalit Health Services, approved the procurement of Inspira's FDA-cleared ART100 platform, marking a significant milestone in the medical device sector for the company.
- Market Reach: The ART100 system will be rapidly deployed across Clalit’s healthcare network, which serves approximately 4.9 million members, indicating a swift expansion of the company's market share and enhanced brand presence.
- Clinical Validation: The approval of ART100 represents not only a successful regulatory clearance but also strong clinical validation for its application in cardiopulmonary bypass and ECMO procedures, signaling substantial future commercial growth potential.
See More
